Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Glanzmann's thrombasthenia secondary prevention

Introduction

Overview

Overview

DDAVP prevents bleeding after dental extraction and minor surgery in patients with milder platelet defects. Glanzmann’s thrombasthenia patients need regular dental visits and must maintain good oral hygiene because the recurrence of gingival bleeding is more in them. These patient should avoid contact sports. Estrogens, platelet transfusion, antifibrinolytic agents, and recombinant human factor VIIa are some other therapies used for treatment/prevention.

Secondary Prevention

Secondary Prevention

DDAVP prevents bleeding after dental extraction and minor surgery in patients with milder platelet defects[1][2]. Glanzmann’s thrombasthenia patients need regular dental visits and must maintain good oral hygiene because the recurrence of gingival bleeding is more in them. These patient should avoid contact sports. Estrogens, platelet transfusion, antifibrinolytic agents, and recombinant human factor VIIa are some other therapies used for treatment/prevention. [3][4][5]

References

References

  1. ↑ Piot B, Sigaud-Fiks M, Huet P, Fressinaud E, Trossaërt M, Mercier J (March 2002). “Management of dental extractions in patients with bleeding disorders”. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 93 (3): 247–50. PMID 11925531.
  2. ↑ Kosch A, Kehrel B, Nowak-Göttl U, Häberle J, Jürgens H (1999). “[Thrombocytic alpha-delta-storage-pool-disease: shortening of bleeding time after infusion of 1-desamino-8-D-arginine vasopressin]”. Klin Padiatr (in German). 211 (4): 198–200. doi:10.1055/s-2008-1043787. PMID 10472549.
  3. ↑ Varkey I, Rai K, Hegde AM, Vijaya MS, Oommen VI (March 2014). “Clinical Management of Glanzmann’s Thrombasthenia: A Case Report”. J Dent (Tehran). 11 (2): 242–7. PMC 4043557. PMID 24910701.
  4. ↑ Solh T, Botsford A, Solh M (2015). “Glanzmann’s thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options”. J Blood Med. 6: 219–27. doi:10.2147/JBM.S71319. PMC 4501245. PMID 26185478.
  5. ↑ Poon MC, Zotz R, Di Minno G, Abrams ZS, Knudsen JB, Laurian Y (January 2006). “Glanzmann’s thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents”. Semin. Hematol. 43 (1 Suppl 1): S33–6. doi:10.1053/j.seminhematol.2005.11.009. PMID 16427383.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2]